2012
DOI: 10.1002/ange.201202414
|View full text |Cite
|
Sign up to set email alerts
|

Cephalosporin‐3′‐diazeniumdiolates: Targeted NO‐Donor Prodrugs for Dispersing Bacterial Biofilms

Abstract: Kampf gegen Biofilme: Mit NO‐Donoren lässt sich ein bakterieller Biofilm dispergieren, und damit können mitverabreichte Antibiotika die empfindlicheren freien Zellen töten. Das chemisch stabile Cephalosporin‐3′‐diazeniumdiolat‐NO‐Donor‐Pharmakon (siehe Schema) wird durch bakterielle β‐Lactamasen aktiviert und erleichtert diese zweistufige Biofilmentfernung.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
41
0
1

Year Published

2013
2013
2017
2017

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 30 publications
(43 citation statements)
references
References 26 publications
1
41
0
1
Order By: Relevance
“…Although nitrobenzene and metal-NO complexes have been proposed as alternative NO-donors due to their stability in aqueous solutions, their practical applications also have been limited because the NO release from these NO-donors requires UV light that is not biomedically benign and has poor tissue penetration [34]. Accordingly, there have been continuous efforts to overcome the intrinsic drawbacks of NO-donors by developing formulations or functional groups capable of protecting unstable NO-donors from triggers and further restricting NO release to specific stimuli [34,62,63,7378]. Second, it is paramount to investigate the mechanism of how the combined NO and drug delivery systems enable reversal of MDR effects and subsequently improve chemotherapy.…”
Section: Conclusion and Perspectivementioning
confidence: 99%
“…Although nitrobenzene and metal-NO complexes have been proposed as alternative NO-donors due to their stability in aqueous solutions, their practical applications also have been limited because the NO release from these NO-donors requires UV light that is not biomedically benign and has poor tissue penetration [34]. Accordingly, there have been continuous efforts to overcome the intrinsic drawbacks of NO-donors by developing formulations or functional groups capable of protecting unstable NO-donors from triggers and further restricting NO release to specific stimuli [34,62,63,7378]. Second, it is paramount to investigate the mechanism of how the combined NO and drug delivery systems enable reversal of MDR effects and subsequently improve chemotherapy.…”
Section: Conclusion and Perspectivementioning
confidence: 99%
“…An innovative new class of NO‐donor prodrugs was described that can liberate NO upon specific activation by bacterial β‐lactamase enzymes. These prodrugs enhance the efficacy of standard antibiotic therapies against in vitro biofilms and thus have significant clinical potential .…”
Section: Highlights: Milestones In Biofilm Researchmentioning
confidence: 99%
“…He has reported in Angewandte Chemie on NO-donor prodrugs for dispersing bacterial biofilms. [4] Cameron Jones (Monash University) is the winner of the H. G. Smith Memorial Award. Jones studied at The University of Western Australia, and was awarded his PhD in 1992 for work supervised by Colin Raston at Griffith University.…”
Section: Royal Australian Chemical Institute Awardsmentioning
confidence: 98%